• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by HilleVax Inc. (Amendment)

    2/14/24 6:46:10 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HLVX alert in real time by email
    SC 13G/A 1 tm245429d40_sc13ga.htm SC 13G/A

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 1)*

     

    HilleVax, Inc. 

    (Name of Issuer)

     

    Common stock, $0.0001 par value per share 

    (Title of Class of Securities)

     

    43157M102 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

    x

    ¨

    Rule 13d-1(b)

    Rule 13d-1(c)

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     


     

    CUSIP No.   43157M102
    1.

    Names of Reporting Persons

    Lightspeed Venture Partners Select IV, L.P.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    2,303,871 shares

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    2,303,871 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,303,871 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.8% (2)

    12.

    Type of Reporting Person (See Instructions)

    PN

             

     

    (1)This Schedule 13G is filed by Lightspeed Venture Partners Select IV, L.P., a Cayman Islands exempted limited partnership (“Lightspeed IV”), Lightspeed General Partner Select IV, L.P., a Cayman Islands exempted limited partnership (“LGP IV”), Lightspeed Ultimate General Partner Select IV, L.L.C., a Cayman Islands limited liability company (“LUGP IV”), Arif Janmohamed (“Janmohamed”) and Ravi Mhatre (“Mhatre” and, with Lightspeed IV, LGP IV, LUGP IV and Janmohamed collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)This calculation is based on 48,437,001 shares of Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 9, 2023 with the Securities and Exchange Commission (the “SEC”).

     

    2

     

     

    CUSIP No.   43157M102
    1.

    Names of Reporting Persons

    Lightspeed General Partner Select IV, L.P.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    2,303,871 shares

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    2,303,871 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,303,871 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.8% (2)

    12.

    Type of Reporting Person (See Instructions)

    PN

             

      

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)This calculation is based on 48,437,001 shares of Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 9, 2023 with the SEC.

      

    3

     

     

    CUSIP No.   43157M102
    1.

    Names of Reporting Persons

    Lightspeed Ultimate General Partner Select IV, L.L.C.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    2,303,871 shares

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    2,303,871 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,303,871 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.8% (2)

    12.

    Type of Reporting Person (See Instructions)

    OO

             

      

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)This calculation is based on 48,437,001 shares of Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 9, 2023 with the SEC.

      

    4

     

     

    CUSIP No.   43157M102
    1.

    Names of Reporting Persons

    Arif Janmohamed

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    2,303,871 shares

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    2,303,871 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,303,871 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.8% (2)

    12.

    Type of Reporting Person (See Instructions)

    IN

             

      

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)This calculation is based on 48,437,001 shares of Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 9, 2023 with the SEC.

     

    5

     

     

    CUSIP No.   43157M102
    1.

    Names of Reporting Persons

    Ravi Mhatre

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    9,561 shares

    6.

    Shared Voting Power

    2,303,871 shares

    7.

    Sole Dispositive Power

    9,561 shares

    8.

    Shared Dispositive Power

    2,303,871 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,313,432 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.8% (2)

    12.

    Type of Reporting Person (See Instructions)

    IN

             

      

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)This calculation is based on 48,437,001 shares of Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 9, 2023 with the SEC.

      

    6

     

     

    Item 1.
      (a)

    Name of Issuer

    HilleVax, Inc.

      (b)

    Address of Issuer’s Principal Executive Offices

    321 Harrison Avenue

    Boston, Massachusetts 02118

     
    Item 2.
      (a)

    Name of Person Filing

    Lightspeed Venture Partners Select IV, L.P. (“Lightspeed IV”)

    Lightspeed General Partner Select IV, L.P. (“LGP IV”)

    Lightspeed Ultimate General Partner Select IV, L.L.C. (“LUGP IV”)

    Arif Janmohamed (“Janmohamed”)

    Ravi Mhatre (“Mhatre”)

      (b)

    Address of Principal Business Office or, if none, Residence

    c/o Lightspeed Venture Partners

    2200 Sand Hill Road

    Menlo Park, CA 94025

      (c) Citizenship  
        Entities: Lightspeed IV     -     Cayman Islands
          LGP IV                 -     Cayman Islands
          LUGP IV              -     Cayman Islands
        Individuals: Janmohamed      -     United States of America
          Mhatre                -     United States of America
      (d)

    Title of Class of Securities

    Common Stock, $0.0001 par value (“Common Stock”)

      (e)

    CUSIP Number

    43157M102

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable

      

    7

     

     

    Item 4. Ownership
    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of December 31, 2023:

     

    Reporting
    Persons
      Shares Held
    Directly
       Sole
    Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Beneficial
    Ownership
       Percentage
    of Class (3)
     
    Lightspeed IV (1)   2,303,871         2,303,871         2,303,871    2,303,871    4.8%
    LGP IV (1)             2,303,871         2,303,871    2,303,871    4.8%
    LUGP IV (1)             2,303,871         2,303,871    2,303,871    4.8%
    Janmohamed (1)             2,303,871         2,303,871    2,303,871    4.8%
    Mhatre (1) (2)   9,561    9,561    2,303,871    9,561    2,303,871    2,313,432    4.8%

     

    (1)    Includes 2,303,871 shares of Common Stock held by Lightspeed IV which may be deemed to be beneficially owned by LGP IV, LUGP IV and Janmohamed and Mhatre because (i) LGP IV is the general partner of Lightspeed IV, (ii) LUGP IV is the general partner of LGP IV and (iii) Janmohamed and Mhatre serve as managers of LUGP IV. Each of the Reporting Persons (other than Lightspeed IV) and each of their affiliated entities and the officers, directors, partners, members and managers thereof, disclaims beneficial ownership of the securities held directly by Lightspeed IV.

     

    (2)    Includes 9,561 shares of Common Stock held by Mhatre who exercises sole voting and dispositive power over such shares.

     

    (3)    This calculation is based on 48,437,001 shares of Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 9, 2023 with the SEC.

     

    Item 5.

    Ownership of Five Percent or Less of a Class 

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x
     
    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person 

      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
      Not applicable
     
    Item 9. Notice of Dissolution of Group
      Not applicable
     
    Item 10. Certification
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
                       

      

    8

     

     

    Signature

      

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Lightspeed Venture Partners Select IV, L.P.  

     

    By: Lightspeed General Partner Select IV, L.P.  
    its General Partner  

     

    By: Lightspeed Ultimate General Partner Select IV, L.L.C.  
    its General Partner  

     

    By:  /s/ Ravi Mhatre  
      Name: Ravi Mhatre  
      Title: Duly Authorized Signatory  

     

    Lightspeed General Partner Select IV, L.P.

     

    By: Lightspeed Ultimate General Partner Select IV, L.L.C.  
    its General Partner  

     

    By: /s/ Ravi Mhatre  
        Name: Ravi Mhatre  
        Title: Duly Authorized Signatory  

     

    Lightspeed Ultimate General Partner Select IV, L.L.C.

     

    By: /s/ Ravi Mhatre  
        Name: Ravi Mhatre  
        Title: Duly Authorized Signatory  

     

    /s/ Arif Janmohamed  
    Arif Janmohamed  
       
    /s/ Ravi Mhatre  
    Ravi Mhatre  

      

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    9

     

      

    Exhibit(s):

     

    AJoint Filing Agreement

     

    10

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of HilleVax, Inc. is filed on behalf of each of us.

     

    Dated: February 14, 2024

     

    Lightspeed Venture Partners Select IV, L.P.  

     

    By: Lightspeed General Partner Select IV, L.P.  
    its General Partner  

     

    By: Lightspeed Ultimate General Partner Select IV, L.L.C.  
    its General Partner  

     

    By:  /s/ Ravi Mhatre  
      Name: Ravi Mhatre  
      Title: Duly Authorized Signatory  

     

    Lightspeed General Partner Select IV, L.P.

     

    By: Lightspeed Ultimate General Partner Select IV, L.L.C.  
    its General Partner  

     

    By: /s/ Ravi Mhatre  
        Name: Ravi Mhatre  
        Title: Duly Authorized Signatory  

     

    Lightspeed Ultimate General Partner Select IV, L.L.C.

     

    By: /s/ Ravi Mhatre  
        Name: Ravi Mhatre  
        Title: Duly Authorized Signatory  

     

    /s/ Arif Janmohamed  
    Arif Janmohamed  
       
    /s/ Ravi Mhatre  
    Ravi Mhatre  

     

     

    Get the next $HLVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLVX

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gerberding Julie L.

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:12 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chu Shelley

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:15 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Hilleman Jeryl L

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:11 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Financials

    Live finance-specific insights

    See more

    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

      BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

      9/1/22 5:18:14 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

      7/9/24 9:48:14 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by Stifel with a new price target

      Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

      7/9/24 7:46:22 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

      7/9/24 7:46:01 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:36:33 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:00:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by HilleVax Inc.

      SC 13G - HilleVax, Inc. (0001888012) (Subject)

      7/22/24 9:02:05 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    SEC Filings

    See more
    • SEC Form 10-Q filed by HilleVax Inc.

      10-Q - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:10:20 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:05:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by HilleVax Inc.

      SCHEDULE 13D - HilleVax, Inc. (0001888012) (Subject)

      5/2/25 4:15:10 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/8/24 4:22:13 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/1/24 4:08:42 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and

      5/8/25 7:00:30 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

      $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 mi

      3/28/25 5:00:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

      Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

      5/9/24 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

      BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

      1/18/24 7:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care